Table 1 Potential for saxagliptin to antagonize binding of radioligands to cardiovascular-related receptors, ion channels, and enzymes
From: Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
Target | L type Ca2+ | GABA-A α1B2γ2 | Cardiac hNAV1.5 | Adrenergic α1β | Muscarinic M2 | ACE | PDE |
|---|---|---|---|---|---|---|---|
IC50 or EC50, μM | >25 | >30 | >30 | >30 | >30 | >60 | >30 |